All News
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Transcranial Stimulation is Effective in Fibromyalgia
A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/P8SKs3JNEx
Dr. John Cush RheumNow ( View Tweet)
🦵🏼💉LOSEIT study: liraglutide led to slight↑ in medial joint space width in knee OA vs placebo (0.22 vs 0.07 mm), but difference not statistically significant (p=0.17). More potent GLP-1RAs may be needed for greater improvement in structural knee OA
@RheumNow #EULAR2025 #OP0223
Mrinalini Dey DrMiniDey ( View Tweet)
GRAPPA defines :
- D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs)
- CM(complex to manage)-PsA (adds pain, comorbidity, complexity).
A needed framework to improve trial design & real-world care.
Do these definitions fit your clinic?
#OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA
Jiha Lee JihaRheum ( View Tweet)
#RITAZAREM: infection risk during RTX induction in AAV was ↑ w/ lung disease & nodules/cavities; ↓ w/ TMP-SMX prophylaxis. Early infections predicted later ones, but risk didn’t differ by RTX vs AZA. Pulmonary damage is a key red flag for infection
@RheumNow #EULAR2025 #OP0167
Mrinalini Dey DrMiniDey ( View Tweet)
29% of new-onset psoriasis pts in Stockholm cohort developed PsA over 9,255 person-years.
Two prediction models (AUC 0.804) identify:
➡ who to refer
➡ who will progress
Key predictors: HLA-B27, CRP, enthesitis, arthralgia.
@RheumNow #EULAR2025 #OP0178:
Jiha Lee JihaRheum ( View Tweet)
The definition of MAS. MAS is secondary HLH. Other causes of secondary HLH are infections, malignancy and iatrogenic.
Georgin-Lavialle S @RheumNow #EULAR2025 https://t.co/CpB78JBlVJ
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Clinical Pearl's for #MAS
Infections are still the most common cause.
Next is malignancy...
Then other causes like autoimmunity..
Ask a detailed history ! Sometimes check with the family when the pt can't give history..
#EULAR2025 @RheumNow https://t.co/fepercz5Af
Bella Mehta bella_mehta ( View Tweet)
Total serum IL 18 can help instead of CDC42 or NLCR4 genetic testing in #MAS
Several monogentic mutations in primary HLH- these panels can be available..
#EULAR2025 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Age of onset is really important when thinking about #MAS
Primary HLH more frequent in pediatric population. But can continue to adulthood.
#EULAR2025 @RheumNow https://t.co/J7xmTiQiwr
Bella Mehta bella_mehta ( View Tweet)
MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state
Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#infections in #JAKi
@drdavidliew
#JAKi sl ⬆️ infection risk vs #TNFi
⬆️HZ w JAKi
JAKi same risk w #latent #TB #LTBI and new TB ⬇️in JAKi v bDMARDs
He didn’t discuss TYK2i
Reassuring - risk⬇️ over time for infection
@RheumNow #EULAR2025 @eular_org
JAKi & infection https://t.co/KVsY2gXVkQ
Links:
Janet Pope Janetbirdope ( View Tweet)
Management of HLH/MAS and modes of action of advanced therapies
Jessica Manson @RheumNow #EULAR2025 https://t.co/Op3u53ZXeK
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
JAKi: expanding RMD indications—but important safety concerns to consider
⚠️ Cancer: Neutral vs MTX/placebo, ↑ risk vs TNF
⚠️ Infection: ↑ with age, disease activity & GC use—not uniformly higher with JAKi
🗣️ Patients rank infection risk as top concern
@rheumnow #EULAR2025 https://t.co/RJRDWQjqNC
Links:
Jiha Lee JihaRheum ( View Tweet)
Age & dose ⬆️ infections in JAKi
Not all JAKi are created w equal risk
@RheumNow @eular_org #EULAR2015 @drdavidliew
#JAKi & #infection https://t.co/F7zLUBuzJR
Janet Pope Janetbirdope ( View Tweet)
Stabilize the pts with HLH with steroids when still trying to figure out the diagnosis of #HLH/ #MAS
Many drugs can be used...but important to balance infection risk with immunosuppression
These are critical pts. Be vigilant..
#EULAR2025 @RheumNow https://t.co/id4ae3SWtj
Links:
Bella Mehta bella_mehta ( View Tweet)
3 Fs of diagnosis of #HLH
-Fever
-Ferritin
-Falling blood count
Raising awareness is the key! Especially in rare diseases like this where the morbidity and mortality is super high!
Collaboration between specialists help
HLH networks will be helpful like this
@RheumNow #EULAR2025 https://t.co/HWbvIma3yx
Bella Mehta bella_mehta ( View Tweet)
In #axSpA post #TNFi-IR
What to use next?
👇
#ATTRA registry
90% #SpA on #bDMARDs are captured
Comparison of
TNFi to ▶️
2nd TNFi vs
#IL17i
▶️No diff in #retention
✅better #BASDAI and other outcomes w TNFi!
❎less safety
🤔
#EULAR2025 @RheumNow @eular_org
Abst#POS0116 https://t.co/7mqFfD4Amf
Janet Pope Janetbirdope ( View Tweet)
#Cancer is not ⬆️in JAKi vs #bDMARDs in
#rheumatoid #arthritis
When adjusted for #confounders
#JAKPOT data
Now you see it (unadjusted ⬆️risk)
Now you don’t (adjusted =#malignancy)
JAKi vs bDMARDs in RA
EULAR2025 @RheumNow @eular_org
#JAK it out! new perspective on JAKi https://t.co/wCQ3dHNAVa
Links:
Janet Pope Janetbirdope ( View Tweet)
Rheumatology #AI to optimize rheumatology triage. Only 53 percent correlation between the AIs diagnosis with rheumatologists final diagnosis. Not sure if we want 47 percent pts to drop off...without a chance for diagnosis?
#POS0883 #EULAR2025 @RheumNow https://t.co/UWsCHG00t1
Bella Mehta bella_mehta ( View Tweet)
